CGC:NSD-Canopy Growth Corporation (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 26.55

Change

-0.62 (-2.28)%

Market Cap

USD 10.46B

Volume

2.46M

Average Target Price

USD 38.78 (+46.05%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis for recreational and medical purposes primarily in Canada, the United States, Germany, and the United Kingdom. It operates through two segments, Cannabis, Hemp and Other Consumer Products; and Canopy Rivers. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. As of February 14, 2020, it operated 28 cannabis retail stores under the Tweed or Tokyo Smoke name. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-22 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
APHA Aphria Inc

-0.22 (-1.59%)

USD4.17B 60.60 454.68
CRON Cronos Group Inc

-0.05 (-0.62%)

USD2.93B 37.00 N/A
PCRX Pacira BioSciences, Inc

-0.65 (-1.00%)

USD2.81B 19.21 44.17
TLRY Tilray, Inc

-0.36 (-2.14%)

USD2.73B N/A N/A
ORGO Organogenesis Holdings Inc

+0.08 (+0.38%)

USD2.62B 128.13 72.14
IRWD Ironwood Pharmaceuticals, Inc

-0.05 (-0.41%)

USD1.75B 16.45 12.68
SUPN Supernus Pharmaceuticals, Inc

-0.09 (-0.29%)

USD1.66B 13.26 7.74
SNDL Sundial Growers Inc

-0.03 (-4.02%)

USD1.40B -99,999.99 N/A

ETFs Containing CGC

Symbol Name Weight Mer Price(Change) Market Cap
CROP IQ Global Agribusiness Sm.. 0.00 % 0.76 %

N/A

USD6.04M
MJ ETFMG Alternative Harvest.. 0.00 % 0.75 %

-0.31 (-1.49%)

USD1.75B
AIIQ AI Powered International .. 0.00 % 0.79 %

-0.08 (-0.25%)

USD9.56M
YOLO AdvisorShares Pure Cannab.. 0.00 % 0.75 %

-0.26 (-1.24%)

USD0.43B
CNBS Amplify Seymour Cannabis .. 0.00 % 0.75 %

-0.22 (-0.83%)

N/A
THCX The Cannabis ETF 0.00 % 0.70 %

+0.01 (+0.06%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.75% 53% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.75% 53% F 51% F
Trailing 12 Months  
Capital Gain 79.15% 80% B- 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 79.15% 80% B- 61% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -5.72% 48% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.72% 48% F 15% F
Risk Return Profile  
Volatility (Standard Deviation) 49.76% 48% F 34% F
Risk Adjusted Return -11.50% 47% F 20% F
Market Capitalization 10.46B 100% A+ 91% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.09 62% D- 50% F
Price / Cash Flow Ratio -13.53 76% C 80% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -48.46% 50% F 24% F
Return on Invested Capital -22.65% 49% F 27% F
Return on Assets -6.49% 63% D 32% F
Debt to Equity Ratio 9.11% 68% D+ 74% C
Technical Ratios  
Short Ratio 3.19 51% F 36% F
Short Percent 12.25% 29% F 16% F
Beta 2.17 15% F 11% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector